DOW has had a wild ride this past year. If you look at the chart, it slid all the way down close to 21 in August, then basically whiplashed back up to the low 40s by spring before giving up ground again. That kind of volatility usually scares me off, but the fact that it’s now cooled off to 34.20 after such a run grabs my attention.
I’m leaning bullish here, with a target of 39.50 in the next couple months. Here’s why: first, chemicals pricing is starting to stabilize after last year’s oversupply drama (that August crater lines up with a glut and weaker demand). DOW’s recent cost cutting moves should start showing up in margins maybe not massive, but enough to get noticed if demand stays steady from here. Also, cyclicals like this tend to catch a tailwind when the market thinks a soft landing is sticking, and right now there’s a lot less recession chatter than six months ago.
Biggest risk is another surprise macro shock or if input costs spike again (energy prices especially). DOW isn’t exactly nimble, and one bad quarter could drag it right back to the 20s so this is not a set and forget play.
The main thing I’m watching for is their next earnings. Anything that hints at better demand in Europe or Asia could be enough to get this moving toward my 39.50 target pretty quickly. If they guide down or talk about more plant shutdowns, I’ll be out in a hurry. Pretty decent risk/reward if you can stomach some chop.
NUE has been an unreal mover over the last year. Just look at the chart: it went from around 120 last summer to crossing 250 now. That's basically doubled in less than twelve months, with most of that rocket fuel coming in the past few months. Not every day you see a boring sounding steel name go vertical like this. So yeah, it's tempting to chase, but I'm still bullish here.
Steel prices keep surprising to the upside, and NUE keeps flexing that cost advantage over the competition. Their vertical integration isn't just a buzzword, it's giving them real margin strength even as other players slap together excuses about "input costs." Plus, if those construction incentives and infrastructure spend rumors turn into action this summer, NUE is set up to be a big winner. The capacity expansions actually look smart in hindsight, not reckless. I like targeting 295.00, so that's about 40 bucks upside from here.
Not calling this risk free. If demand takes a sudden dive or steel prices correct, NUE could just as easily chill out or even give up some of these fast gains. It's not trading at fire sale multiples anymore after this run. But if earnings next quarter show management actually guiding higher, I think this rips again. This one's going to be all about how the next couple months play out on the macro side.
ALL has basically been bouncing up and down for a year, but mostly in this same range. You look at the last 12 months and it's hard to call this anything but a choppy sideways ride lots of swings but no real breakout or breakdown. That actually makes me more bullish right now, not less. I feel like there's a reset going on and buyers keep stepping in every time it dips under 200.
My target is 248.65, which is about 20 percent up from here. The main reasons: first, underwriting quality seems solid even with all the drama in property insurance these days. They're able to push through higher premiums and maintain retention, which is no small feat with everyone shopping their rates. Second, I think expense ratios have quietly improved, but the market hasn't really rewarded that yet. You could see margin expansion if they stay disciplined and don't chase unprofitable growth (big 'if', but recent quarters show a clear trend).
The risk for me is obviously weather. If another catastrophic hurricane season hits, ALL is gonna get smoked again and this whole thesis falls apart for a bit. That's just the price of betting on insurers. The positive catalyst I'm watching is the next earnings report if they beat and guide above the Street, I expect a sharp move up, since sentiment has been pretty lukewarm all year. If it doesn't play out after that, maybe time to move on and find something with more juice.
TRV looks kind of stuck in a weird spot after the rollercoaster of the last year. It bounced around the mid 260s to mid 290s for months, then suddenly shot up past $310 in early March. But that didn't really stick, and now it's just under $300 again. Honestly feels like the market isn't quite sure how to value this thing with the macro backdrop changing every month.
I'm leaning bearish here, at least short term. My target is $269.94. This feels realistic given that TRV couldn't hold above $310 and there's been steady drift lower since the April bounce. Reinsurance costs look like they're finally biting, and you can see it in the choppiness of the last few months. Don't love how much catastrophe exposure they still have, especially if hurricane season ends up being rougher than forecast. Also, commercial insurance pricing is starting to head down just as claim costs are up. That's not a great combo.
The big risk is that we get some upside surprise out of their Q2 earnings. If reserve releases are better than feared or they somehow squeeze more out of the investment portfolio, there's a shot this bounces right back to $305. But for now, I think we see more sideways to lower trading.
I'd be watching for commentary from their management on how they're handling inflation in loss costs and any early guidance on 2026 pricing. If they signal things are stabilizing or they can pass along more rate, I'd reconsider. But for now, feels like risk skews down. Not a "panic sell" but definitely not parking money here for the next few months.
SYK has been on a wild ride this past year. It hit above 400 just last summer, then basically trended down for months, with some nasty dips, especially this spring. That last leg down from around 340 in April to sub 300 in May was rough. Seeing it now hover around 316, it feels like a lot of the panic is probably in the price. Not exactly the timing anyone dreams of, but here we are.
I’m leaning bullish from here. Stryker still has a solid pipeline, especially with elective procedures and hospital CapEx starting to pick back up. The company’s execution has always stood out, and the demographic tailwind isn’t going away joint replacements and robotics are still long term growth drivers. If hospital budgets are normalizing (and recent management commentary suggested as much), their end markets could start looking a lot less soft over the next couple quarters.
I’m targeting 372.00 over the next 8 weeks. That lines up with the upper range of where it traded a few months ago, before the selloff got vicious. It’s not a hail mary moonshot, just a retrace to a more reasonable multiple if you figure growth picks back up. To get there, I’m expecting at least one solid earnings print or upbeat guidance to break this dead money trend.
The risk is pretty obvious: if hospital spending disappoints, or Stryker guides down again, the stock can easily retest the lows. Plus, if margin pressure shows up in the next report, you’re back in the penalty box. Not pretending there’s no risk, just think the risk/reward makes sense here with most of the recent pain already priced in.
That ADP nosedive over the past year has been pretty wild. Just last summer it was hanging out around 320, and here we are at 225.31. The drop from fall into early spring was brutal (saw it dip under 200 at one point), and while there’s been a little bounce lately, it still feels like the dust hasn’t totally settled. So yeah, I’m bullish from here, but this is definitely a more medium risk shot for me.
There’s real value to be had with ADP at these levels. The company’s core business payroll and HR software is still sticky as hell. Churn stays low because once companies are plugged in, it’s not worth the pain to switch. Plus, as labor markets stay tight, employers keep spending on these platforms to stay compliant and organized. Not flashy, but steady. I’m also thinking the recent cost cutting and automation pushes are going to start showing up in margins over the next few quarters.
If they get any positive surprises out of client adds or guide higher on their next earnings call, the stock should climb back toward 260.00. That’s my target price. It’s not back to former highs, but it’s a decent recovery, and I don’t see the old support around 200 breaking without a macro shock. The main risk? Corporate budgets are slimming down if there’s a true recession and companies tighten up even more, you could see deal delays or a squeeze on ADP’s pricing power. That would drag out the recovery a lot longer.
Earnings next quarter are the big one to watch. If management sounds upbeat or books show stabilization, I think we finally get a break in the negative sentiment. Until then, just gotta stay patient with this one. Anyone else holding through the chop?
Looking at Colgate Palmolive (CL), I’m leaning bullish here even though the last year’s chart has been messy. If you scroll back, CL was sliding from the high 90s in February down to sub 80 by October, but since then it’s clawed back up. We’re now hovering around 90.44, and that’s after a couple of strong bursts earlier this year. So, not a rocket ship, but not dead money either.
My target is 106.00 in the next 18 weeks. That’s not wild upside, but in this market defensive names with steady cash flows are something I actually want to own. CL has decent pricing power, especially given how sticky consumer staples are even when things tighten up. On top of that, input costs (like packaging and raw materials) seem to be stabilizing, which should help margins hold up or even improve into the next couple of quarters. Their brand portfolio is massive, and they’ve managed to pass on price hikes without too much volume loss.
Caveat: one real risk I see is consumer pushback if they raise prices again this year. If we see another inflation shock or even just flat household spending, shoppers will trade down. That could ding both volumes and perception, though CL’s brands usually weather the storm better than most.
Biggest catalyst I’m watching is their Q3 earnings in a few months. If they deliver even a small beat and guide with confidence on costs, the stock could finally get out of this sideways funk. Wouldn’t shock me to see some multiple expansion if there’s any hint of margin upside. Sitting tight and adding on dips for now.
FTNT has been on a pretty wild ride over the past year. If you look at the price action, it was hanging above 100 for a while before the sudden collapse last August (dropped all the way into the 70s), then just sort of meandered and bounced between 76 and 86 for months. Now it’s shot right back up to 115, so whoever held through that is probably feeling smug.
I’m bullish here with a target of 135.25. The recent runup looks aggressive, but I think it’s finally getting credit for its shift toward recurring subscription revenue. That model’s sticky, and a bunch of big security contracts have landed since December. It’s not just hype; their last couple quarters actually showed solid billings growth. The market’s just waking up to the rerate potential.
Biggest risk? The competition. Palo Alto and CrowdStrike aren’t sitting still, and FTNT’s sales execution was pretty rough last summer (hence that crater). If new bookings slip again, this stock will get smacked right back down. So this isn’t one to go overweight on for me. But if next earnings show another beat, especially on margins, that could give it the juice for another leg up.
Keep your eye on the next quarter’s billings guide. If management sounds confident and gives a number north of expectations, I think the rerating continues. If not, well, be ready for a quick exit.
CI has been all over the place this year. Just looking at the price swings since last summer up to 330 at one point, down to 263 not long ago, and now around 288 you can tell this isn’t the sort of slow, steady healthcare stock some people expect. The volatility says a lot about where investor confidence is right now.
I'm leaning bullish here, with a target of 316.00 over the next couple months. The biggest driver is that the recent pullback from last fall’s highs has mostly been about broad sector rotation and not something fundamentally broken at Cigna. Their core insurance business is still printing cash, and pharmacy benefits haven’t slowed as much as the bears were hoping. If they can show any decent growth or margin improvement in the next earnings season, I think we’ll see a snapback.
It’s not all smooth sailing. Reimbursement pressure and policy tweaks are always lurking, and any surprise from regulators could knock this back down quick. That’s the main risk I see if guidance gets trimmed, the stock could hang out in the 270s for a while. But if management holds the line and posts a clean quarter, money will rotate back into defensive names like this.
Main thing I’m watching is the next earnings call. If CI puts up solid numbers and doesn’t guide down, that could be the green light for a run back toward 316.00. Not a moonshot, but the setup looks solid for a 10 percent move from here.
OKTA has definitely been on a wild ride lately. If you look at the last year, the stock dropped off a cliff from the 120s last May and never really recovered. It's been stuck in this downward to sideways trend since, with a few half hearted pop and drop moments. Lately it's been hovering just above 75, but at 83.90 now, I think there's actually a decent risk reward for a modest bullish trade here.
The core argument: Okta's identity management business is a sticky subscription model that should still ride the broad secular trend toward cloud security, even if their growth has slowed a ton. They've finally started to get a grip on their sales churn and operational mess from last year, which honestly tanked confidence. If management can show just a couple of clean quarters, I think sentiment shifts quickly and the market gives them a bit more respect. My target is 99.00, which is pretty much where it traded back in January before that aggressive slide in March.
There's definitely a risk that this thing is just dead money if they keep missing on execution or give cautious guidance again. Investors have a long memory with stocks like this and it's burned a lot of folks already. So yeah, if they botch the next earnings or fail to impress on new deals, you could easily see another selloff. But on the flip side, with expectations this low, any beat and raise could really get things moving in a hurry.
Next earnings will be the catalyst, and I'm watching for any signs of stabilization in revenue and gross margin. If that comes through, it could be enough to get OKTA out of its rut. Not the most exciting thesis, but the setup looks decent for a 15 20 percent move if they deliver.
